347 related articles for article (PubMed ID: 31941438)
41. Caffeine and cannabinoid receptors modulate impulsive behavior in an animal model of attentional deficit and hyperactivity disorder.
Leffa DT; Ferreira SG; Machado NJ; Souza CM; Rosa FD; de Carvalho C; Kincheski GC; Takahashi RN; Porciúncula LO; Souza DO; Cunha RA; Pandolfo P
Eur J Neurosci; 2019 Jun; 49(12):1673-1683. PubMed ID: 30667546
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
Childress A; Hoo-Cardiel A; Lang P
Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
[No Abstract] [Full Text] [Related]
43. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness.
Scahill L
CNS Drugs; 2009; 23 Suppl 1():43-9. PubMed ID: 19621977
[TBL] [Abstract][Full Text] [Related]
44. [An update on the pharmacological treatment of attention deficit hyperactivity disorder: lisdexamphetamine and extended-release guanfacine].
Martin Fernandez-Mayoralas D; Fernandez-Perrone AL; Munoz-Jareno N; Fernandez-Jaen A
Rev Neurol; 2017 Mar; 64(s02):S1-S8. PubMed ID: 28272733
[TBL] [Abstract][Full Text] [Related]
45. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents.
Connor DF; Grasso DJ; Slivinsky MD; Pearson GS; Banga A
J Child Adolesc Psychopharmacol; 2013 May; 23(4):244-51. PubMed ID: 23683139
[TBL] [Abstract][Full Text] [Related]
46. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
[TBL] [Abstract][Full Text] [Related]
47. Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists.
Fernando AB; Economidou D; Theobald DE; Zou MF; Newman AH; Spoelder M; Caprioli D; Moreno M; Hipólito L; Aspinall AT; Robbins TW; Dalley JW
Psychopharmacology (Berl); 2012 Jan; 219(2):341-52. PubMed ID: 21761147
[TBL] [Abstract][Full Text] [Related]
48. Deficient neural activity subserving decision-making during reward waiting time in intertemporal choice in adult attention-deficit hyperactivity disorder.
Todokoro A; Tanaka SC; Kawakubo Y; Yahata N; Ishii-Takahashi A; Nishimura Y; Kano Y; Ohtake F; Kasai K
Psychiatry Clin Neurosci; 2018 Aug; 72(8):580-590. PubMed ID: 29687930
[TBL] [Abstract][Full Text] [Related]
49. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience.
Chappell PB; Riddle MA; Scahill L; Lynch KA; Schultz R; Arnsten A; Leckman JF; Cohen DJ
J Am Acad Child Adolesc Psychiatry; 1995 Sep; 34(9):1140-6. PubMed ID: 7559307
[TBL] [Abstract][Full Text] [Related]
50. Modeling and simulation of the exposure-response and dropout pattern of guanfacine extended-release in pediatric patients with ADHD.
Knebel W; Rogers J; Polhamus D; Ermer J; Gastonguay MR
J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):45-65. PubMed ID: 25373474
[TBL] [Abstract][Full Text] [Related]
51. Association between Early Guanfacine Discontinuation and Somnolence for Attention-Deficit/Hyperactivity Disorder.
Doi K; Sogawa R; Eguchi Y; Matsuo M; Shimanoe C
Biol Pharm Bull; 2024; 47(6):1204-1208. PubMed ID: 38910124
[TBL] [Abstract][Full Text] [Related]
52. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder.
Taylor FB; Russo J
J Clin Psychopharmacol; 2001 Apr; 21(2):223-8. PubMed ID: 11270920
[TBL] [Abstract][Full Text] [Related]
53. Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).
Sallee FR; Eaton K
Expert Opin Pharmacother; 2010 Oct; 11(15):2549-56. PubMed ID: 20831361
[TBL] [Abstract][Full Text] [Related]
54. Effect of ADHD medication in male C57BL/6J mice performing the rodent Continuous Performance Test.
Caballero-Puntiverio M; Lerdrup LS; Grupe M; Larsen CW; Dietz AG; Andreasen JT
Psychopharmacology (Berl); 2019 Jun; 236(6):1839-1851. PubMed ID: 30656365
[TBL] [Abstract][Full Text] [Related]
55. Choice-impulsivity in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): A meta-analytic review.
Patros CH; Alderson RM; Kasper LJ; Tarle SJ; Lea SE; Hudec KL
Clin Psychol Rev; 2016 Feb; 43():162-74. PubMed ID: 26602954
[TBL] [Abstract][Full Text] [Related]
56. Treatment Efficacy of Combined Sertraline and Guanfacine in Comorbid Obsessive-Compulsive Disorder and Attention Deficit/Hyperactivity Disorder: Two Case Studies.
Taormina SP; Galloway MP; Rosenberg DR
J Dev Behav Pediatr; 2016; 37(6):491-5. PubMed ID: 27011005
[TBL] [Abstract][Full Text] [Related]
57. The Atxn7-overexpressing mice showed hyperactivity and impulsivity which were ameliorated by atomoxetine treatment: A possible animal model of the hyperactive-impulsive phenotype of ADHD.
Dela Peña IJI; Botanas CJ; de la Peña JB; Custodio RJ; Dela Peña I; Ryoo ZY; Kim BN; Ryu JH; Kim HJ; Cheong JH
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jan; 88():311-319. PubMed ID: 30125623
[TBL] [Abstract][Full Text] [Related]
58. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
[TBL] [Abstract][Full Text] [Related]
59. Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity.
McCracken JT; Aman MG; McDougle CJ; Tierney E; Shiraga S; Whelan F; Arnold LE; Posey D; Ritz L; Vitiello B; Scahill L
J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):1-5. PubMed ID: 20166790
[TBL] [Abstract][Full Text] [Related]
60. Guanfacine's mechanism of action in treating prefrontal cortical disorders: Successful translation across species.
Arnsten AFT
Neurobiol Learn Mem; 2020 Dec; 176():107327. PubMed ID: 33075480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
